AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03172520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial Nerve Monitor
Description: The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
Study NCT01237106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVM
Description: all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
Study NCT01006863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
Study NCT01006863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
Study NCT01006863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine \[group 5 (n=30)\] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
Study NCT05117047 — intervention group
Intervention type: PROCEDURE
Intervention: liver resection
Description: After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
Study NCT03106506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
Study NCT02287324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation
Study NCT03106506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
Study NCT03912025 — intervention group
Intervention type: OTHER
Intervention: Relationship between positive mindset and exercise capacity
Description: No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
Study NCT03227562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RisperiDONE 0.5 MG
Description: To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
Study NCT01990924 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 15 FPS
Description: X-ray pictures
Study NCT01990924 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 7.5 FPS
Description: X-ray pictures
Study NCT01771718 — intervention group
Intervention type: DEVICE
Intervention: MPTflex-multiphoton microscopy-based tomograph.
Description: non-invasive optical biopsy
Study NCT04635072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stabilised Whole Rice Bran
Description: Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
Study NCT01407497 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA HIVIS and MVA-CMDR
Description: 600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
Study NCT01407497 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA HIVIS and MVA-CMDR
Description: 1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
Study NCT01407497 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
Study NCT01407497 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
Study NCT02012608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Oral glutamine for subjects undergoing breast conserving therapy
Study NCT02012608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For subjects undergoing breast conserving therapy
Study NCT01718509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: 50 or 70 mg administered orally, once-daily for up to 12 weeks
Study NCT01718509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once-daily, orally, for up to 12 weeks
Study NCT02004912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentoring intervention
Description: The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
Study NCT03075176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized LASIK
Description: Wavefront optimized laser vision correction
Study NCT03075176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized Photorefractive Keratectomy
Description: Wavefront optimized laser vision correction
Study NCT03075176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography-guided LASIK
Description: Topography-guided laser vision correction
Study NCT03075176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography-guided Photorefractive Keratectomy
Description: Topography-guided laser vision correction
Study NCT00129805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-9042
Study NCT00129805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT01131624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulphate
Description: 200 mg iron per day in a convenient dosage schedule.
Study NCT01131624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: 1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
Study NCT02808338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips BiPAP AutoSV Advanced System One
Description: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
Study NCT02808338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Philips BiPAP ASV
Description: This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
Study NCT02808338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S7 VPAP Adapt
Description: This device is FDA approved and will be set to predetermined setting.
Study NCT02808338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S9 VPAP Adapt
Description: This device is FDA approved and will be set to predetermined setting.
Study NCT02287324 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Manual Contact
Study NCT02658565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
Study NCT05344144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
Study NCT05344144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
Study NCT01044238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: 18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
Study NCT01044238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: 18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
Study NCT02864940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumosity
Description: A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
Study NCT02864940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossword puzzle
Description: This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
Study NCT00370695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulation System
Description: Stimulation turned on from implant throughout the Study
Study NCT01258101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks
Study NCT03126487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIGH INTENSITY FOCUSED ULTRASOUND
Description: HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
Study NCT05951426 — intervention group
Intervention type: PROCEDURE
Intervention: 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
Description: 1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium
Study NCT02983409 — intervention group
Intervention type: RADIATION
Intervention: Pstone
Description: A adult patients who were diagnosed as urinary stone by the urinary CT
Study NCT00600340 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and Paclitaxel
Description: A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
Study NCT00600340 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and Capecitabine
Description: B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
Study NCT04798677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABBC1 Immunoessential
Description: Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
Study NCT04798677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for dissolution in water, excipents. Lemon flavor
Study NCT01602484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-prepared Splint Pack composed by Medline
Description: Applying splint by using pre-prepared splint pack
Study NCT01602484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk splint supplies
Description: Applying splint by using the bulk splint supplies
Study NCT03551093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISS SPG stimulation
Description: The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
Study NCT04754464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: synbiotic
Description: Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
Study NCT04754464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
Study NCT02697357 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychosocial Instruments
Study NCT02697357 — intervention group
Intervention type: BEHAVIORAL
Intervention: Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
Study NCT04600284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg
Study NCT03025217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Lifestyle Coaching (TLC)
Study NCT03054467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caduet 10Mg-20Mg Tablet
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Study NCT03054467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorvasC® 10 mg Tablets
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Study NCT03864718 — intervention group
Intervention type: PROCEDURE
Intervention: photodynamic therapy
Description: Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide 2.5 mg
Description: During treatment, participants receive IV vintafolide 2.5 mg.
Study NCT04600284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2102
Description: AD-2102 25mg
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel 80 mg/m^2
Description: During treatment, participants receive IV paclitaxel 80 mg/m\^2.
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m^2
Description: During treatment, participants receive IV paclitaxel 80 mg/m\^2.
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etarfolatide
Description: During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide
Description: During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
Study NCT01258101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 16 weeks
Study NCT01258101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 800 mg orally daily
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication for Paclitaxel
Description: During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
Study NCT01953536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premedication for Paclitaxel
Description: During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
Study NCT03810417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin Antibodies Fab Fragments
Description: Digoxin antibodies
Study NCT03810417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT06156514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
Study NCT06156514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
Study NCT02645383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PASCAL laser
Description: A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
Study NCT02645383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laser
Description: Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
Study NCT01415037 — intervention group
Intervention type: PROCEDURE
Intervention: annular array ultrasound exam
Description: For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
Study NCT03039127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Description: Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.